Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of $0.44, $0.13 better than the analyst estimate of $0.31. Revenue for the quarter came in at $217.8 million versus the consensus estimate of $192.29 million.

"Maravai had an incredibly strong first half of 2021, and we feel very good about the momentum we are seeing across our business,” said Carl Hull, Chairman and CEO. “In particular, we anticipate continued robust growth in our Nucleic Acid Production business, and we are increasing our guidance to reflect stronger demand expectations for the remainder of the year,” added Hull.

GUIDANCE:

Maravai LifeSciences sees FY2021 revenue of $745-770 million, versus the consensus of $709.65 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.